TRACER and the UMCG consolidate expertise to accelerate COVID-19 treatments and vaccines
Tuesday 31 March 2020
- Life Cooperative
Unique Profit-Free Consortium Releases Immediate Capacity and Infrastructure to Accelerate COVID-19 Treatments and Vaccine Research.
TRACER B.V and the University Medical Center Groningen (UMCG) have consolidated their efforts, expertise and infrastructure to accelerate the drug development of COVID-19 treatments and vaccines, which are urgently needed and studied by multiple R&D groups around the world.
The COVID-19 RAPID CURE TASK FORCE is offering the global community unique access to immediately generate in-human data on a potential COVID-19 treatment or vaccine by providing:
• Hot and Cold GMP facilities for clinical nuclear and fluorescent labeling
• Nuclear and fluorescent in-human state-of-the-art imaging facilities
• Clinical equipment and machinery such as digital PET/CT scanners and fluorescent cameras for lung imaging
• Staffing and priority time slots to conduct imaging in patients
• Guidance and expertise by world renowned scientists from academia and industry
Among the core team are Prof. Rudi Dierckx and Prof. Andor Glaudemans from the Medical Imaging Center at the UMCG and Prof. Erik Frijlink from the Department of Pharmaceutical Technology and Biopharmacy. Prof. Erik Frijlink states, “As pharmacists we are committed to provide the safest, most efficient and effective treatment to the patients with COVID-19. We support this TASK FORCE with all knowledge, technology and expertise as is currently already underway with treatment measures like developments for intra-pulmonary hydroxychloroquine installment for the patients with COVID-19 within the RAPID CURE TASK FORCE”.
TRACER will provide its unique expertise in nuclear / fluorescent labeling and imaging to generate fast in-human biodistribution, pharmacokinetic and on- and off-target data. This data allows scientists and drug developers to very quickly see whether their therapeutic compound reaches the lungs efficiently, where it acts on the virus present.
Prof. Go van Dam (CEO at TRACER) emphasizes “In these extraordinary times in the world due to COVID-19, we need to act FAST and combine ALL our scientific knowledge, research infrastructure together with biotech-pharma industry to deliver the fastest cure possible for patients with COVID-19 and the global society as a whole. Only focused approaches and innovative technologies can reduce the time to treatment – we need to act NOW!”
Source: RAPID CURE TASK FORCE
Image: TRACER B.V.
Focus areas
Life CooperativeLatest news
-
Thursday 5 November 2020
Start-up Reperio developing diagnostic technology for glau..
-
Monday 21 September 2020
Campus ecosystem invests in SG Papertronics
-
Wednesday 16 September 2020
First patients treated in First-in-Human Trial for Polygan..
-
Tuesday 15 September 2020
InnoCore Pharmaceuticals to develop long-acting injectable..
-
Wednesday 9 September 2020
Agreement signed for new Innovation Center Chemistry and E..
-
Wednesday 2 September 2020
Campus Community Fund invests 500 million euros in Campus ..
-
Thursday 6 August 2020
Pharma Connect Capital invests in Hercules Pharmaceuticals..
-
Tuesday 4 August 2020
OFINEXT 100% part of the Ofichem Group
-
Friday 26 June 2020
On the way to 'one size fits all' tracer
-
Wednesday 10 June 2020
QPS hopeful about drug for corona patients

English
Nederlands